ViiV Healthcare has today announced that it is committing to license its patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) and is entering into negotiation on voluntary licensing terms with the UN-backed Medicines Patent Pool (MPP). ViiV Healthcare and MPP are working to agree terms and execute a voluntary licence as quickly as possible to help enable at scale access to cabotegravir LA for PrEP in low- and middle-income countries. This builds on a long-standing partnership between ViiV Healthcare and MPP which has been highly successful in facilitating the manufacture and sale...
Login or create a forever free account to read this news
Sign up/Log in